RELAY THERAPEUTICS INC

Insider selling continues at Relay Therapeutics—Peter Rahmer sells 4,508 shares for $20.03 each, a routine liquidity move that may impact investor sentiment.

SoftBank Vision Fund’s sale of 6 million Relay Therapeutics shares is a routine rebalancing move, not a signal of concern. Stay tuned to insider trades, regulatory milestones, and the company’s protein‑degrading pipeline for the true drivers of futu…

Patel Sanjiv’s 48,199‑share sale at Relay Therapeutics shows disciplined insider liquidity while keeping a large stake, highlighting strong governance and ongoing confidence in the oncology pipeline.

Relay Therapeutics CFO sells 1,459 shares at $18.61—an example of disciplined insider activity that signals stability, not volatility, for investors eyeing its oncology pipeline.

Relais Therapeutics insider sale: President sells 8,660 shares under Rule 10b5‑1 amid 10.5% weekly gain, 426% YTD rise—insightful for investors on disciplined portfolio shifts.

Insightful analysis of Relay Therapeutics’ CFO Catinazzo Thomas’s 10b5‑1 trades: disciplined buying, selling at discount, and insider confidence signals for investors.

Insider option purchase by Maz Claire Mazumdar shows renewed confidence in Relay Therapeutics’ oncology strategy and capital‑planning move to expand equity flexibility.

Relay Therapeutics CFO sells 972 shares at $14.79 to cover RSU taxes; the routine transaction shows modest insider activity and stability amid Phase III zovegalisib trials.

Relay Therapeutics CFO sells shares as part of a disciplined, rule‑based liquidity plan, signaling confidence amid strong regulatory progress and market gains.

Relay Therapeutics CFO’s 17,717‑share sale is a routine liquidity move, not a sign of distress – still bullish on the company’s oncology pipeline and FDA milestones.